Digital Therapeutics Market

The global digital therapeutics market is projected to reach USD 35.37 billion by 2031 from USD 10.95 billion in 2026, at a CAGR of 26.4% from 2026 to 2031. The rising prevalence of chronic diseases, increasing healthcare expenditure, growing demand for personalized remote care, and the shift toward value-based healthcare are driving the adoption of digital therapeutics (DTx) across healthcare providers, payers, employers, and pharmaceutical companies. According to the World Health Organization (WHO), noncommunicable diseases (NCDs) account for approximately 43 million deaths annually, representing 75% of all deaths worldwide. In the US, the Centers for Disease Control and Prevention (CDC) estimates that 90% of the nation’s annual healthcare expenditure is spent on individuals with chronic and mental health conditions. These trends are accelerating the adoption of evidence-based DTx solutions leveraging technologies such as artificial intelligence (AI), cognitive behavioral therapy (CBT), remote patient monitoring (RPM), wearable integration, and mobile health applications to improve disease management and patient outcomes. Additionally, the American Medical Association (AMA) reports that digital therapeutics are among the digital health technologies with the highest planned future adoption by physicians, while evolving regulatory frameworks and reimbursement pathways are further supporting market growth. However, the market continues to face challenges related to limited reimbursement, evolving regulatory requirements, data privacy and cybersecurity concerns, patient engagement, and integration with existing clinical workflows.

Prominent players in the digital therapeutics market include Teladoc Health, Inc. (US), Noom, Inc. (US), Omada Health Inc. (US), Hinge Health, Inc. (US), DarioHealth Corp. (US), and Sword Health, Inc. (Portugal), among others. These companies adopted strategies such as product launches, expansions, agreements, partnerships, collaborations, and acquisitions to strengthen their market presence in the digital therapeutics market. In June 2026, Noom launched a free GLP-1 Companion that provides medication education, symptom tracking, and personalized lifestyle guidance to support individuals using GLP-1 therapies. In May 2026, Omada Health joined Lilly Employer Connect to expand employer access to its lifestyle support program for employees prescribed GLP-1 therapies, complementing obesity treatment with behavioral coaching.

To know about the assumptions considered for the study download the pdf brochure

Teladoc Health, Inc. has established a strong position in the digital therapeutics market through its comprehensive portfolio of virtual care and digital health solutions spanning chronic condition management, mental health, and preventive care. The company supports healthcare providers, payers, employers, and patients by delivering evidence-based digital therapeutics, remote patient monitoring, virtual consultations, and personalized care programs that improve clinical outcomes and expand access to care. Teladoc continues to strengthen its market position by enhancing the quality and safety of its digital care offerings. For instance, in May 2026, BetterHelp, a Teladoc Health company, joined the Institute of Patient Safety and Quality of Virtual Care, the first federally listed Patient Safety Organization (PSO) dedicated to virtual care. This partnership enables BetterHelp to systematically identify safety risks, analyze clinical data, and continuously improve the quality of virtual mental healthcare delivery. Additionally, Teladoc continues to expand its capabilities through strategic partnerships, product innovation, and investments aimed at advancing evidence-based digital care and improving patient outcomes globally.

Noom, Inc. has established a strong position in the digital therapeutics market through its AI-powered behavior change platform focused on weight management, obesity, diabetes prevention, and metabolic health. The company supports individuals, employers, and healthcare partners by delivering personalized digital therapeutic programs that combine psychology-based coaching, nutrition guidance, and continuous health monitoring to improve long-term clinical outcomes. Noom continues to strengthen its market position through artificial intelligence-driven innovation. For instance, in October 2025, the company launched Noom Health Scan, an AI-powered facial scan technology that uses smartphone cameras to estimate key health indicators, including heart rate, heart rate variability, and skin age, providing users with real-time metabolic health insights and personalized recommendations. This innovation enhances user engagement and expands Noom's preventive health capabilities. Additionally, the company continues to strengthen its digital therapeutics portfolio through AI-enabled product development and strategic partnerships aimed at advancing personalized, data-driven chronic disease management.

Hinge Health, Inc. is a leading provider of digital musculoskeletal (MSK) care solutions, offering clinically validated digital therapeutic programs for musculoskeletal disorders, chronic pain, and pelvic health. The company serves employers, health plans, and healthcare providers through AI-enabled care pathways, wearable motion tracking, personalized exercise therapy, and multidisciplinary clinical support to improve patient outcomes and reduce healthcare costs. Hinge Health continues to expand its digital therapeutics portfolio by addressing adjacent chronic conditions. For instance, in April 2026, the company launched its Comprehensive Migraine Care Program, integrating personalized education, behavioral health support, physical therapy, and care navigation to help individuals manage migraine symptoms and associated musculoskeletal conditions. This expansion broadens Hinge Health's therapeutic offerings and reinforces its position as a comprehensive digital care provider for chronic conditions.

Market Ranking

The digital therapeutics market comprises established digital health companies and specialized software providers that deliver evidence-based therapeutic interventions through clinically validated software to prevent, manage, and treat a broad range of chronic and behavioral health conditions. Key players such as Teladoc Health, Inc., Noom, Inc., Omada Health Inc., Hinge Health, Inc., DarioHealth Corp., Sword Health, Inc., Virta Health Corp, Welldoc, Inc., Click Therapeutics, Inc., Resmed, Sidekick Health, Akili, Inc., AppliedVR, Inc., Wellthy Therapeutics Pvt Ltd, Headspace Inc., Lark Technologies, Inc., XRHealth, Amalgam Rx, Inc., Aptar Digital Health, Canary Health, Freespira, Mindable Health GmbH, GET.ON Institut fur Online Gesundheitstrainings GmbH, CogniFit Inc., and Morrow Inc. offer solutions across diabetes, obesity, musculoskeletal disorders, cardiovascular diseases, respiratory diseases, mental health, neurological disorders, substance use disorders, and other chronic conditions. These companies have established strong market positions through clinically validated therapeutic programs, robust software platforms, strategic collaborations with healthcare providers, payers, employers, and pharmaceutical companies, as well as expanding global commercial presence. Additionally, continued innovation in artificial intelligence (AI), digital biomarkers, remote patient monitoring, wearable device integration, immersive technologies (VR/AR), personalized behavioral interventions, and real-world data analytics is intensifying competition and accelerating the adoption of digital therapeutics across the global healthcare ecosystem.

Related Reports:

Digital Therapeutics/DTx Market by Offering (Software, Immersive), Application (Treatment (Diabetes, CNS, CVD, Rehab), Preventive), Revenue (Subscription, Enterprise), Channel (B2B, B2C), End User (Hospitals, Payers, Employers) - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]